Alexion Pharmaceuticals
AstraZeneca Closes Mega $39B Alexion Buyout
AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases. AZ on Wednesday announced the completion of its Alexion acquisition, a week after securing a pivotal nod from the UK’s Competition and Markets Authority (CMA). […]
AstraZeneca’s $39B Alexion Buy Clears FTC Review
AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company stated. The Cambridge, UK, pharmaceutical and biotechnology company said the US clearance follows competition clearances in Canada, Brazil, Russia, and other countries globally. “Additional global regulatory clearances are pending, including but […]
Featured News
Massachusetts Forces Apartment Sales as Condition of $69 Billion Landlord Merger
Aug 19, 2026 by
CPI
Papa John’s Wins Final Approval for $5 Million No-Poach Settlement
Aug 18, 2026 by
CPI
Apple Revamps EU App Store Rules in Deal With Regulators
Aug 18, 2026 by
CPI
South Korean Prosecutors Raid Conglomerate Over Alleged Stock Manipulation
Aug 18, 2026 by
CPI
Andreessen Horowitz Faces Justice Department Antitrust Scrutiny Over AI Board Seats
Aug 18, 2026 by
CPI
Antitrust Mix
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes